AstraZeneca Asks Fed. Circ. To Reopen Nexium Patent Suit

Law360, New York (September 5, 2013, 8:06 PM EDT) -- AstraZeneca AB on Tuesday asked the Federal Circuit to revive its suit against Hanmi Pharmaceutical Co. Ltd., arguing a lower court had wrongly found that the South Korean drugmaker’s copycat version of the acid reflux medication Nexium does not violate AstraZeneca's patents.

In its brief, AstraZeneca argues that U.S. District Judge Joel Pisano wrongly interpreted the definition of “alkaline salt” to find that the active ingredient in Hanmi’s planned product didn't fall under the alkaline salt category. Nexium’s active ingredient is an alkaline magnesium salt of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.